In a significant move for India’s diabetes treatment landscape, Eris Lifesciences has entered into a strategic partnership with Natco Pharma to commercialize semaglutide in India. The collaboration aims to strengthen access to advanced therapies for type 2 diabetes and metabolic disorders.
The companies plan to introduce semaglutide in the Indian market following regulatory approval. The partnership combines Natco’s manufacturing capabilities with Eris’s strong domestic marketing and distribution network, particularly in chronic and specialty therapies.
Natco Pharma has received approval from the Central Drugs Standard Control Organization to manufacture semaglutide in India. This regulatory clearance enables the companies to move forward with commercialization plans.
Under the agreement, Natco will manufacture the product, while Eris will lead marketing and distribution across India. The companies intend to leverage Eris’s established presence among endocrinologists, diabetologists, and general physicians to ensure rapid market penetration.
Financial details of the agreement have not been disclosed.
Semaglutide is a GLP-1 receptor agonist widely used for managing type 2 diabetes and, in certain formulations, for weight management. The molecule was originally developed by Novo Nordisk and has become one of the most prescribed therapies globally in metabolic care.
With India facing a growing diabetes burden, the introduction of domestically manufactured semaglutide is expected to improve affordability and accessibility. The move aligns with the increasing demand for innovative yet cost effective chronic therapies.
Eris Lifesciences has consistently focused on expanding its footprint in chronic therapies, including diabetes and cardiometabolic care. The addition of semaglutide strengthens its portfolio in the high growth metabolic segment.
Company leadership described semaglutide as a significant advancement in diabetes treatment. The partnership reflects Eris’s strategy to scale its specialty offerings and deepen its engagement in complex therapies.
India remains one of the countries most affected by type 2 diabetes. The availability of semaglutide through domestic manufacturing partnerships is expected to enhance treatment options for patients and physicians.
(Rh/ARC)
